{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T09:09:04Z","timestamp":1788340144261,"version":"build-2803163510"},"reference-count":139,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T00:00:00Z","timestamp":1650326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81960043, 82160043"],"award-info":[{"award-number":["81960043, 82160043"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20192ACB20030"],"award-info":[{"award-number":["20192ACB20030"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Epstein Barr virus (EBV) can affect 90% of the human population. It can invade B lymphocytes, T lymphocytes and natural killer cells of the host and remain in the host for life. The long latency and reactivation of EBV can cause malignant transformation, leading to various lymphoproliferative diseases (LPDs), including EBV-related B-cell lymphoproliferative diseases (EBV-B-LPDs) (for example, Burkitt lymphoma (BL), classic Hodgkin\u2019s lymphoma (cHL), and posttransplantation and HIV-related lymphoproliferative diseases) and EBV-related T-cell lymphoproliferative diseases (EBV-T\/NK-LPDs) (for example, extranodal nasal type natural killer\/T-cell lymphoma (ENKTCL), aggressive NK cell leukaemia (ANKL), and peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS). EBV-LPDs are heterogeneous with different clinical features and prognoses. The treatment of EBV-LPDs is usually similar to that of EBV-negative lymphoma with the same histology and can include chemotherapy, radiotherapy, and hematopoietic stem cell transplant (HSCT). However, problems such as serious toxicity and drug resistance worsen the survival prognosis of patients. EBV expresses a variety of viral and lytic proteins that regulate cell cycle and death processes and promote the survival of tumour cells. Based on these characteristics, a series of treatment strategies for EBV in related malignant tumours have been developed, such as monoclonal antibodies, immune checkpoint inhibitors, cytotoxic T lymphocytes (CTLs) and epigenetic therapy. These new individualized therapies can produce highly specific killing effects on tumour cells, and nontumour cells can be protected from toxicity. This paper will focus on the latest progress in the treatment of EBV-LPDs based on pathological mechanisms.<\/jats:p>","DOI":"10.3389\/fonc.2022.838817","type":"journal-article","created":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T13:36:16Z","timestamp":1650375376000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Treatment Advances in EBV Related Lymphoproliferative Diseases"],"prefix":"10.3389","volume":"12","author":[{"given":"Kebing","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2018.00417","article-title":"Overview of EBV-Associated T\/NK-Cell Lymphoproliferative Diseases","volume":"6","author":"Kimura","year":"2018","journal-title":"Front Pediatr"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32049","article-title":"High Risk Epstein-Barr Virus Variants Characterized by Distinct Polymorphisms in the EBER Locus are Strongly Associated With Nasopharyngeal Carcinoma","volume":"144","author":"Hui","year":"2019","journal-title":"Int J Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00081","article-title":"Viral-Targeted Strategies Against EBV-Associated Lymphoproliferative Diseases","volume":"9","author":"Hui","year":"2019","journal-title":"Front Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206548","article-title":"Virally Targeted Therapies for EBV-Associated Malignancies","volume":"22","author":"Israel","year":"2003","journal-title":"Oncogene"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2005.11.003","article-title":"Cytokine Mediated Induction of the Major Epstein-Barr Virus (EBV)-Encoded Transforming Protein, LMP-1","volume":"104","author":"Kis","year":"2006","journal-title":"Immunol Lett"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2009.07.004","article-title":"Burkitt's Lymphoma: The Rosetta Stone Deciphering Epstein-Barr Virus Biology","volume":"19","author":"Rowe","year":"2009","journal-title":"Semin Cancer Biol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2569","article-title":"IL-10 can Induce the Expression of EBV-Encoded Latent Membrane Protein-1 (LMP-1) in the Absence of EBNA-2 in B Lymphocytes and in Burkitt Lymphoma- and NK Lymphoma-Derived Cell Lines","volume":"107","author":"Kis","year":"2006","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2008-0036","article-title":"EBV-Associated Lymphoproliferative Disorders: Classification and Treatment","volume":"13","author":"Carbone","year":"2008","journal-title":"Oncol"},{"key":"B9","article-title":"Epstein Barr virus and its replication","author":"Kieff","year":"2001","journal-title":"Fields Virology"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01001-07","article-title":"Unique Signaling Properties of CTAR1 in LMP1-Mediated Transformation","volume":"81","author":"Mainou","year":"2007","journal-title":"J Virol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra032015","article-title":"Persistence of the Epstein-Barr Virus and the Origins of Associated Lymphomas","volume":"350","author":"Thorley-Lawson","year":"2004","journal-title":"New Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(64)91524-7","article-title":"Virus Particles in Cultured Lymphoblasts from Burkitt's Lymphoma","volume":"1","author":"Epstein","year":"1964","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-06-538504","article-title":"How I Treat Burkitt Lymphoma in Adults","volume":"124","author":"Jacobson","year":"2014","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61177-X","article-title":"Burkitt's Lymphoma","volume":"379","author":"Molyneux","year":"2012","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/jco.1996.14.3.925","article-title":"Adults and Children With Small non-Cleaved-Cell Lymphoma Have a Similar Excellent Outcome When Treated With the Same Chemotherapy Regimen","volume":"14","author":"Magrath","year":"1996","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq677","article-title":"Evaluation of the Addition of Rituximab to CODOX-M\/IVAC for Burkitt's Lymphoma: A Retrospective Analysis","volume":"22","author":"Barnes","year":"2011","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21776","article-title":"Chemoimmunotherapy With Hyper-CVAD Plus Rituximab for the Treatment of Adult Burkitt and Burkitt-Type Lymphoma or Acute Lymphoblastic Leukemia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12736","article-title":"Improved Efficacy Using Rituximab and Brief Duration, High Intensity Chemotherapy With Filgrastim Support for Burkitt or Aggressive Lymphomas: Cancer and Leukemia Group B Study 10 002","volume":"165","author":"Rizzieri","year":"2014","journal-title":"Br J Haematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20143","article-title":"Intensive Chemotherapy With and Without Cranial Radiation for Burkitt Leukemia and Lymphoma: Final Results of Cancer and Leukemia Group B Study 9251","volume":"100","author":"Rizzieri","year":"2010","journal-title":"Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1308392","article-title":"Low-Intensity Therapy in Adults With Burkitt's Lymphoma","volume":"369","author":"Dunleavy","year":"2013","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.84","article-title":"Reduced PTLD-Related Mortality in Patients Experiencing EBV Infection Following Allo-SCT After the Introduction of a Protocol Incorporating Pre-Emptive Rituximab","volume":"48","author":"van der Velden","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2019.00295","article-title":"Refractory Epstein-Barr Virus (EBV)-Related Post-Transplant Lymphoproliferative Disease: Cure by Combined Brentuximab Vedotin and Allogeneic EBV-Specific T-Lymphocytes","volume":"6","author":"Mika","year":"2019","journal-title":"Front Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2019.1636981","article-title":"Response to Daratumumab in Rituximab-Resistant EBV-Associated PTLD Following Allogenic Stem Cell Transplantation From an EBV Seronegative Donor","volume":"60","author":"Strunz","year":"2019","journal-title":"Leukemia Lymphoma"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for Classical Hodgkin's Lymphoma After Failure of Both Autologous Stem-Cell Transplantation and Brentuximab Vedotin: A Multicentre, Multicohort, Single-Arm Phase 2 Trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123162","article-title":"PET-Adapted Nivolumab or Nivolumab Plus ICE As First Salvage Therapy in Relapsed or Refractory Hodgkin Lymphoma","volume":"134","author":"Herrera","year":"2019","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed\/Refractory Classic Hodgkin Lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30192-3","article-title":"Safety and Activity of Sintilimab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (ORIENT-1): A Multicentre, Single-Arm, Phase 2 Trial","volume":"6","author":"Pys","year":"2019","journal-title":"Lancet Haematol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0545-2","article-title":"Treatment of Relapsed or Refractory Classical Hodgkin Lymphoma With the Anti-PD-1, Tislelizumab: Results of a Phase 2, Single-Arm, Multicenter Study","volume":"34","author":"Song","year":"2020","journal-title":"Leukemia"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1680","article-title":"Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma","volume":"25","author":"Song","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-122576","article-title":"Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-Up Results From the Single-Arm Phase 1\/2 Study","volume":"134","author":"Moskowitz","year":"2019","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1182\/blood-2020-136384","article-title":"Consolidation With Nivolumab and Brentuximab Vedotin After Autologous Hematopoietic Cell Transplantation in Patients With High-Risk Hodgkin Lymphoma","volume":"136","author":"Herrera","year":"2020","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30275-1","article-title":"Brentuximab Vedotin Plus Nivolumab as First-Line Therapy in Older or Chemotherapy-Ineligible Patients With Hodgkin Lymphoma (ACCRU): A Multicentre, Single-Arm, Phase 2 Trial","volume":"7","author":"Cheson","year":"2020"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e13302","DOI":"10.1111\/petr.13302","article-title":"Successful Nivolumab Therapy in an Allogeneic Stem Cell Transplant Child With Post-Transplant Lymphoproliferative Disorder","volume":"22","author":"Kassa","year":"2018","journal-title":"Pediatr Transplantation"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220946462","article-title":"Classical Hodgkin Lymphoma-Like Post-Transplant Lymphoproliferative Disease After Allogeneic Stem Cell Transplantation for Primary Myelofibrosis is Successfully Treated With Nivolumab: A Case Report","volume":"27","author":"Gunes","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 Expression Is Characteristic of a Subset of Aggressive B-Cell Lymphomas and Virus-Associated Malignancies","volume":"19","author":"Chen","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-11-320481","article-title":"Viral Induction and Targeted Inhibition of Galectin-1 in EBV+ Posttransplant Lymphoproliferative Disorders","volume":"117","author":"Ouyang","year":"2009","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.8.2925.2925_2925_2934","article-title":"Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes for the Treatment of Patients With EBV-Positive Relapsed Hodgkin's Disease","volume":"91","author":"Roskrow","year":"1998","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-04-844472","article-title":"How I Treat Burkitt Lymphoma in Children, Adolescents, and Young Adults in Sub-Saharan Africa","volume":"132","author":"Gopal","year":"2018","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910460509","article-title":"Detection of EBV Gene Expression in Reed-Sternberg Cells of Hodgkin's Disease","volume":"46","author":"Wu","year":"2010","journal-title":"Int J Cancer"},{"key":"B40","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/0140-6736(91)90943-J","article-title":"Expression of Epstein-Barr Virus Latent Gene Products in Tumour Cells of Hodgkin's Disease","volume":"337","author":"Pallesen","year":"1991","journal-title":"Lancet"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.7.2319","article-title":"Human Immunodeficiency Virus-Associated Hodgkin's Disease Derives From Post-Germinal Center B Cells","volume":"93","author":"Carbone","year":"1999","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2021.1942831","article-title":"Phase II Single-Arm Study of Brentuximab Vedotin in Chinese Patients With Relapsed\/Refractory Classical Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma","volume":"14","author":"Song","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-099317","article-title":"A Phase 1 Multidose Study of SGN-30 Immunotherapy in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies","volume":"111","author":"Bartlett","year":"2008","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/00000478-200301000-00003","article-title":"Senile EBV+ B-Cell Lymphoproliferative Disorders: A Clinicopathologic Study of 22 Patients","volume":"27","author":"Oyama","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202001_22836","article-title":"Clinical Features and Survival Impact of EBV-Positive Diffuse Large B-Cell Lymphoma With Different Age Cutoffs","volume":"24","author":"Nan","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B46","doi-asserted-by":"publisher","first-page":"12168","DOI":"10.1038\/srep12168","article-title":"Epstein-Barr Virus Positive Diffuse Large B-Cell Lymphoma Predict Poor Outcome, Regardless of the Age","volume":"5","author":"Lu","year":"2015","journal-title":"Sci Rep"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2011.07.003","article-title":"EBV-Positive Diffuse Large B-Cell Lymphoma in Young Immunocompetent Individuals","volume":"11","author":"Beltran","year":"2011","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28942","article-title":"Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma Association is Not Only Restricted to Elderly Patients","volume":"135","author":"Cohen","year":"2015","journal-title":"Int J Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.27845","article-title":"Epstein-Barr Virus Presence in Pediatric Diffuse Large B-Cell Lymphoma Reveals a Particular Association and Latency Patterns: Analysis of Viral Role in Tumor Microenvironment","volume":"132","author":"Cohen","year":"2012","journal-title":"Int J Cancer"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2015.01.011","article-title":"Epstein-Barr Virus\u2013Positive Diffuse Large B-Cell Lymphoma in Children: A Disease Reminiscent of Epstein-Barr Virus\u2013Positive Diffuse Large B-Cell Lymphoma of the Elderly","volume":"46","author":"Uccini","year":"2015","journal-title":"Hum Pathol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu556","article-title":"EBV-Positive Diffuse Large B-Cell Lymphoma in Young Adults: Is This a Distinct Disease Entity","volume":"26","author":"Hong","year":"2015","journal-title":"Ann Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 Revision of the World Health Organization Classification of Lymphoid Neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-01-067769","article-title":"The Impact of Epstein-Barr Virus Status on Clinical Outcome in Diffuse Large B-Cell Lymphoma","volume":"110","author":"Park","year":"2007","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00109","article-title":"Epstein Barr Virus Associated B-Cell Lymphomas and Iatrogenic Lymphoproliferative Disorders","volume":"9","author":"Crombie","year":"2019","journal-title":"Front Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.6287","article-title":"Phase II Study of SMILE Chemotherapy for Newly Diagnosed Stage IV, Relapsed, or Refractory Extranodal Natural Killer (Nk)\/T-Cell Lymphoma, Nasal Type: The NK-Cell Tumor Study Group Study","volume":"29","author":"Yamaguchi","year":"2011","journal-title":"J Clin Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0153","article-title":"DDGP Versus SMILE in Newly Diagnosed Advanced Natural Killer\/T-Cell Lymphoma: A Randomized Controlled, Multicenter, Open-Label Study in China","author":"Li","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8647","article-title":"Efficacy of Combined Gemcitabine, Oxaliplatin and Pegaspargase (P-Gemox Regimen) in Patients With Newly Diagnosed Advancedstage or Relapsed\/Refractory Extranodal NK\/T-Cell Lymphoma","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001451","article-title":"Nationwide Survey of Systemic Chronic Active EBV Infection in Japan in Accordance With the New WHO Classification","volume":"4","author":"Yonese","year":"2020","journal-title":"Blood Adv"},{"key":"B59","article-title":"Selection of New Immunotherapy Targets for NK\/T Cell Lymphoma","volume":"12","author":"Lv","year":"2020","journal-title":"Am J Trans Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13045-020-01020-y","article-title":"Daratumumab Monotherapy for Patients With Relapsed or Refractory Natural Killer\/T-Cell Lymphoma, Nasal Type: An Open-Label, Single-Arm, Multicenter, Phase 2 Study","volume":"14","author":"Huang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.5045\/br.2015.50.4.254","article-title":"Complete Remission in CD30-Positive Refractory Extranodal NK\/T-Cell Lymphoma With Brentuximab Vedotin","volume":"50","author":"Kyung","year":"2015","journal-title":"Blood Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2627-9","article-title":"Complete Remission of Refractory Disseminated NK\/T Cell Lymphoma With Brentuximab Vedotin and Bendamustine","volume":"95","author":"Poon","year":"2016","journal-title":"Ann Hematol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769075","article-title":"A Major Turning Point in NK\/T-Cell Lymphoma","author":"Jaccard","year":"2017","journal-title":"Blood J Am Soc Hematol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13045-018-0559-7","article-title":"Activity of Pembrolizumab in Relapsed\/Refractory NK\/T-Cell Lymphoma","volume":"11","author":"Li","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3127-2","article-title":"PD1 Blockade With Low-Dose Nivolumab in NK\/T Cell Lymphoma Failing L-Asparaginase: Efficacy and Safety","author":"Chan","year":"2017","journal-title":"Ann Hematol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41392-021-00768-0","article-title":"Sintilimab for Relapsed\/Refractory Extranodal NK\/T Cell Lymphoma: A Multicenter, Single-Arm, Phase 2 Trial (ORIENT-4)","volume":"6","author":"Tao","year":"2021","journal-title":"Signal Transduction Targeted Ther"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007247","article-title":"Avelumab for the Treatment of Relapsed or Refractory Extranodal NK\/T-Cell Lymphoma: An Open-Label Phase 2 Study","volume":"136","author":"Kim","year":"2020","journal-title":"Blood"},{"key":"B68","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13045-021-01033-1","article-title":"Efficacy and Safety of Geptanolimab (GB226) for Relapsed or Refractory Peripheral T Cell Lymphoma: An Open-Label Phase 2 Study (Gxplore-002)","volume":"14","author":"Shi","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-017-0004-x","article-title":"Oncogenic Activation of JAK3-STAT Signaling Confers Clinical Sensitivity to PRN371, a Novel Selective and Potent JAK3 Inhibitor, in Natural Killer\/T-Cell Lymphoma","author":"Nairisma?Gi","year":"2018","journal-title":"Leukemia"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12529","article-title":"Tofacitinib Induces G1 Cell-Cycle Arrest and Inhibits Tumor Growth in Epstein-Barr Virus-Associated T and Natural Killer Cell Lymphoma Cells","volume":"7","author":"Ando","year":"2016","journal-title":"Oncotarget"},{"key":"B71","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","article-title":"Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins","volume":"32","author":"Bollard","year":"2013","journal-title":"J Clin Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2015.91","article-title":"Long-Term Outcome of Extranodal Nk\/T Cell Lymphoma Patients Treated With Postremission Therapy Using EBV LMP1 and LMP2a-Specific CTLs","author":"Cho","year":"2015","journal-title":"Mol Ther"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12418","article-title":"Anti-Tumor Effects of Suberoylanilide Hydroxamic Acid on Epstein\u2013Barr Virus-Associated T Cell and Natural Killer Cell Lymphoma","volume":"105","author":"Siddiquey","year":"2014","journal-title":"Cancer Sci"},{"key":"B74","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","article-title":"Results From a Multicenter, Open-Label, Pivotal Phase II Study of Chidamide in Relapsed or Refractory Peripheral T-Cell Lymphoma","volume":"26","author":"Shi","year":"2015","journal-title":"Ann Oncol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn431","article-title":"Phase I Study of Proteasome Inhibitor Bortezomib Plus CHOP in Patients With Advanced, Aggressive T-Cell or NK\/T-Cell Lymphoma","author":"Lee","year":"2008","journal-title":"Ann Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.4207","article-title":"Phase II Trial of Proteasome Inhibitor Bortezomib in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma","volume":"25","author":"Zinzani","year":"2007","journal-title":"J Clin Oncol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2010.516272","article-title":"A Promising New Regimen for the Treatment of Advanced Extranodal NK\/T Cell Lymphoma","volume":"50","author":"Farid","year":"2011","journal-title":"Acta Oncol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-196908000-00033","article-title":"Primary Malignancy in Patients Undergoing Immunosuppression for Renal Transplantation","volume":"8","author":"McKhann","year":"1969","journal-title":"Transplantation"},{"key":"B80","article-title":"Malignant Lymphomas in Transplantation Patients","volume":"1","author":"Penn","year":"1969","journal-title":"Transplant Proc"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-0670-3","article-title":"Epstein-Barr Virus and Cancer","volume":"10","author":"Thompson","year":"2004","journal-title":"Clin Cancer Res"},{"key":"B82","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.autrev.2007.02.012","article-title":"B Lymphocytes and Epstein-Barr Virus: The Lesson of Post-Transplant Lymphoproliferative Disorders","volume":"7","author":"Dolcetti","year":"2008","journal-title":"Autoimmun Rev"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0000000000000445","article-title":"Management of Post-Transplant Lymphoproliferative Disorders","volume":"29","author":"Llaurador","year":"2017","journal-title":"Curr Opin Pediatr"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy","volume":"18","author":"Green","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000324","article-title":"Pembrolizumab in Relapsed or Refractory Hodgkin Lymphoma: 2-Year Follow-Up of KEYNOTE-087","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000215","article-title":"PD-1 Blockade With Pembrolizumab for Classical Hodgkin Lymphoma After Autologous Stem Cell Transplantation","volume":"134","author":"Armand","year":"2019","journal-title":"Blood"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-811224","article-title":"Interim Results of Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma","volume":"131","author":"Herrera","year":"2018","journal-title":"Blood"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-567453","article-title":"Immune Checkpoint Blockade in Hematologic Malignancies","volume":"125","author":"Armand","year":"2015","journal-title":"Blood"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.6.3.215","article-title":"Improving T Cell Therapy for Cancer","volume":"6","author":"Foster","year":"2006","journal-title":"Expert Opin Biol Ther"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1126\/science.1352912","article-title":"Restoration of Viral Immunity in Immunodeficient Humans by the Adoptive Transfer of T Cell Clones","volume":"257","author":"Riddell","year":"1992","journal-title":"Science"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199409083311017","article-title":"Donor T Cells to Treat EBV-Associated Lymphoma","volume":"331","author":"Heslop","year":"1994","journal-title":"N Engl J Med"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199404283301703","article-title":"Infusions of Donor Leukocytes to Treat Epstein-Barr Virus-Associated Lymphoproliferative Disorders After Allogeneic Bone Marrow Transplantation","volume":"330","author":"Papadopoulos","year":"1994","journal-title":"N Engl J Med"},{"key":"B93","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1182\/blood-2011-08-371971","article-title":"Adoptive Immunotherapy With Unselected or EBV-Specific T Cells for Biopsy-Proven EBV+ Lymphomas After Allogeneic Hematopoietic Cell Transplantation","volume":"119","author":"Doubrovina","year":"2012","journal-title":"Blood"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-12-063008","article-title":"Allogeneic Cytotoxic T-Cell Therapy for EBV-Positive Posttransplantation Lymphoproliferative Disease: Results of a Phase 2 Multicenter Clinical Trial","volume":"110","author":"Haque","year":"2007","journal-title":"Blood"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/9.suppl_5.S21","article-title":"Immune Escape Mechanisms in Hodgkin's Disease","volume":"9","author":"Poppema","year":"1998","journal-title":"Ann Oncol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/nm1296-1379","article-title":"Epstein-Barr Virus-Driven Gene Therapy for EBV-Related Lymphomas","volume":"2","author":"Franken","year":"1997","journal-title":"Nat Med"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0215(20000815)87:4<606::AID-IJC23>3.0.CO;2-O","article-title":"Efficacy of Ionizing Radiation Combined With Adenoviral P53 Therapy in EBV-Positive Nasopharyngeal Carcinoma","volume":"87","author":"Li","year":"2015","journal-title":"Int J Cancer"},{"key":"B98","article-title":"Tumor-Targeted Gene Therapy for Nasopharyngeal Carcinoma","volume":"62","author":"Li","year":"2002","journal-title":"Cancer Res"},{"key":"B99","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3390\/microorganisms9010180","article-title":"Chronic Active Epstein\u2013Barr Virus Infection: The Elucidation of the Pathophysiology and the Development of Therapeutic Methods","volume":"9","author":"Arai","year":"2021","journal-title":"Microorganisms"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-017-2192-6","article-title":"How We Treat Chronic Active Epstein-Barr Virus Infection","volume":"105","author":"Sawada","year":"2017","journal-title":"Int J Hematol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-11-316745","article-title":"Characterization and Treatment of Chronic Active Epstein-Barr Virus Disease: A 28-Year Experience in the United States","volume":"117","author":"Cohen","year":"2011","journal-title":"Blood"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02488-0","article-title":"Blood Stem-Cell Transplantation for Chronic Active Epstein-Barr Virus With Lymphoproliferation","volume":"356","author":"Takayuki","year":"2000","journal-title":"Lancet"},{"key":"B103","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/bmt.2010.122","article-title":"Excellent Outcome of Allogeneic Hematopoietic SCT With Reduced-Intensity Conditioning for the Treatment of Chronic Active EBV Infection","volume":"46","author":"Kawa","year":"2011","journal-title":"Bone Marrow Transplantation"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-381921","article-title":"EBV-Associated T\/NK-Cell Lymphoproliferative Diseases in Nonimmunocompromised Hosts: Prospective Analysis of 108 Cases","volume":"119","author":"Kimura","year":"2011","journal-title":"Blood"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.3","article-title":"Hematopoietic Stem Cell Transplantation for Adults With EBV-Positive T- or NK-Cell Lymphoproliferative Disorders: Efficacy and Predictive Markers","volume":"51","author":"Arai","year":"2016","journal-title":"Bone Marrow Transplantation"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2359-2","article-title":"CD38 Expression Predicts Poor Prognosis and Might be a Potential Therapy Target in Extranodal NK\/T Cell Lymphoma, Nasal Type","volume":"94","author":"Wang","year":"2015","journal-title":"Ann Hematol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1605684","article-title":"Targeting CD38 in Refractory Extranodal Natural Killer Cell-T-Cell Lymphoma","volume":"375","author":"Hari","year":"2016","journal-title":"New Engl J Med"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1186\/s40880-017-0212-9","article-title":"CD30 Expression in Extranodal Natural Killer\/T-Cell Lymphoma, Nasal Type Among 622 Cases of Mature T-Cell and Natural Killer-Cell Lymphoma at a Single Institution in South China","volume":"36","author":"Feng","year":"2017","journal-title":"Chin J Cancer"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.2217\/imt.14.9","article-title":"Harnessing the Power of the Immune System via Blockade of PD-1 and PD-L1: A Promising New Anticancer Strategy","volume":"6","author":"Reiss","year":"2014","journal-title":"Immunotherapy"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25780","article-title":"STAT3 is Constitutively Activated in Chronic Active Epstein-Barr Virus Infection and can be a Therapeutic Target","volume":"9","author":"Onozawa","year":"2018","journal-title":"Oncotarget"},{"key":"B111","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1097\/PAS.0b013e3181cc7e79","article-title":"PD-1 Expression in T-Cell Lymphomas and Reactive Lymphoid Entities: Potential Overlap in Staining Patterns Between Lymphoma and Viral Lymphadenitis","volume":"34","author":"Krishnan","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24945","article-title":"Suberoylanilide Hydroxamic Acid Induces Viral Lytic Cycle in Epstein-Barr Virus-Positive Epithelial Malignancies and Mediates Enhanced Cell Death","volume":"126","author":"Hui","year":"2010","journal-title":"Int J Cancer"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.27439","article-title":"Activation of Lytic Cycle of Epstein-Barr Virus by Suberoylanilide Hydroxamic Acid Leads to Apoptosis and Tumor Growth Suppression of Nasopharyngeal Carcinoma","volume":"131","author":"Hui","year":"2012","journal-title":"Int J Cancer"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.67.12.7654-7658.1993","article-title":"Epstein-Barr Virus Induces Fragmentation of Chromosomal DNA During Lytic Infection","volume":"67","author":"Kawanishi","year":"1993","journal-title":"J Virol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.2217\/epi.12.52","article-title":"A Focus on the Preclinical Development and Clinical Status of the Histone Deacetylase Inhibitor, Romidepsin (Depsipeptide, Istodax())","volume":"4","author":"Harrison","year":"2012","journal-title":"Epigenomics"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29698","article-title":"Inhibition of Class I Histone Deacetylases by Romidepsin Potently Induces Epstein-Barr Virus Lytic Cycle and Mediates Enhanced Cell Death With Ganciclovir","volume":"138","author":"Hui","year":"2016","journal-title":"Int J Cancer"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv596","article-title":"Epstein-Barr Virus Reactivation in Extranodal Natural Killer\/T-Cell Lymphoma Patients: A Previously Unrecognized Serious Adverse Event in a Pilot Study With Romidepsin","volume":"27","author":"Kim","year":"2016","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2021.105063","article-title":"Sildenafil Prevents HDACi-Induced Epstein-Barr Virus Reactivation Through the PKG Pathway in NK\/T Cell Lymphoma; Potential Implications for HDACi-Mediated Fatal Complications","volume":"189","author":"Kim","year":"2021","journal-title":"Antiviral Res"},{"key":"B119","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1158\/1078-0432.CCR-06-0170","article-title":"United States Food and Drug Administration Approval Summary: Bortezomib for the Treatment of Progressive Multiple Myeloma After One Prior Therapy","volume":"12","author":"Kane","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-332379","article-title":"Bortezomib Induction of C\/Ebp\u03b2 Mediates Epstein-Barr Virus Lytic Activation in Burkitt Lymphoma","volume":"117","author":"Shirley","year":"2011","journal-title":"Blood"},{"key":"B121","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1038\/nm.1864","article-title":"Bortezomib-Induced Enzyme-Targeted Radiation Therapy in Herpesvirus-Associated Tumors","volume":"14","author":"Fu","year":"2008","journal-title":"Nat Med"},{"key":"B122","doi-asserted-by":"publisher","first-page":"13052","DOI":"10.1038\/s41598-017-13533-7","article-title":"Bortezomib Promotes KHSV and EBV Lytic Cycle by Activating JNK and Autophagy","volume":"7","author":"Granato","year":"2017","journal-title":"Sci Rep"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M802968200","article-title":"Tumor-Derived Variants of Epstein-Barr Virus Latent Membrane Protein 1 Induce Sustained Erk Activation and C-Fos","volume":"283","author":"Vaysberg","year":"2008","journal-title":"J Biol Chem"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.2217\/fon.09.53","article-title":"Role of the Epstein-Barr Virus-Encoded Latent Membrane Protein-1, LMP1, in the Pathogenesis of Nasopharyngeal Carcinoma","volume":"5","author":"Morris","year":"2009","journal-title":"Future Oncol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4914(02)02315-8","article-title":"Proteasome Inhibition: A Novel Approach to Cancer Therapy","volume":"8","author":"Adams","year":"2002","journal-title":"Trends Mol Med"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1042\/bj3400127","article-title":"Inhibition of Ubiquitin-Proteasome Pathway Activates a Caspase-3-Like Protease and Induces Bcl-2 Cleavage in Human M-07e Leukaemic Cells","volume":"340","author":"Zhang","year":"1999","journal-title":"Biochem J"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA117.000667","article-title":"Hyaluronan and Proteoglycan Link Protein 1 (HAPLN1) Activates Bortezomib-Resistant NF-Kappa B Activity and Increases Drug Resistance in Multiple Myeloma","volume":"293","author":"Huynh","year":"2018","journal-title":"J Biol Chem"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2295","article-title":"Virus-Associated Tumor Imaging by Induction of Viral Gene Expression","volume":"13","author":"Fu","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-072900","article-title":"Proteasome Inhibitor Bortezomib-Induced Apoptosis in Natural Killer (NK)-Cell Leukemia and Lymphoma: An In Vitro and In Vivo Preclinical Evaluation","volume":"110","author":"Shen","year":"2007","journal-title":"Blood"},{"key":"B130","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2013.115","article-title":"CRM1 Inhibition Induces Tumor Cell Cytotoxicity and Impairs Osteoclastogenesis in Multiple Myeloma: Molecular Mechanisms and Therapeutic Implications","volume":"28","author":"Tai","year":"2014","journal-title":"Leukemia"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.18632\/oncoscience.304","article-title":"XPO1, Therapeutic And Prognostic Target in Sarcomas","volume":"3","author":"Bertucci","year":"2016","journal-title":"Oncoscience"},{"key":"B132","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13045-016-0338-2","article-title":"CRM1\/XPO1 is Associated With Clinical Outcome in Glioma and Represents a Therapeutic Target by Perturbing Multiple Core Pathways","volume":"9","author":"Liu","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.73.8.6872-6881.1999","article-title":"Association With the Cellular Export Receptor CRM 1 Mediates Function and Intracellular Localization of Epstein-Barr Virus SM Protein, a Regulator of Gene Expression","volume":"73","author":"Boyle","year":"1999","journal-title":"J Virol"},{"key":"B134","doi-asserted-by":"publisher","first-page":"9852494","DOI":"10.1155\/2016\/9852494","article-title":"Exosomes in Human Immunodeficiency Virus Type I Pathogenesis: Threat or Opportunity","volume":"2016","author":"Sin-Yeang","year":"2016","journal-title":"Adv Virol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2015.06.029","article-title":"Exosome Mediated Communication Within the Tumor Microenvironment","volume":"219","author":"Milane","year":"2015","journal-title":"J Controlled Release"},{"key":"B136","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/1471-2407-6-283","article-title":"Exosomes Released by EBV-Infected Nasopharyngeal Carcinoma Cells Convey the Viral Latent Membrane Protein 1 and the Immunomodulatory Protein Galectin 9","volume":"6","author":"Keryer-Bibens","year":"2006","journal-title":"BMC Cancer"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02470-14","article-title":"Exosomal Communication Goes Viral","volume":"89","author":"Meckes","year":"2015","journal-title":"J Virol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2014.66","article-title":"Exosomal Hif1\u03b1 Supports Invasive Potential of Nasopharyngeal Carcinoma-Associated LMP1-Positive Exosomes","volume":"33","author":"Aga","year":"2014","journal-title":"Oncogene"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju363","article-title":"Effect of Nasopharyngeal Carcinoma-Derived Exosomes on Human Regulatory T Cells","volume":"107","author":"Mrizak","year":"2015","journal-title":"JNCI J Natl Cancer Institute"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.838817\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T13:36:24Z","timestamp":1650375384000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.838817\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,19]]},"references-count":139,"alternative-id":["10.3389\/fonc.2022.838817"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.838817","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,19]]},"article-number":"838817"}}